Pancreatic tumors are usually diagnosed at an advanced stage in the progression of the disease, thus reducing the survival chances of the patients. Non-invasive early detection would greatly enhance therapy and survival rates. Toward this aim, we investigated in a pilot study the power of methylation changes in whole blood as predictive markers for the detection of pancreatic tumors. We investigated methylation levels at selected CpG sites in the CpG rich regions at the promoter regions of p16, RARbeta, TNFRSF10C, APC, ACIN1, DAPK1, 3OST2, BCL2 and CD44 in the blood of 30 pancreatic tumor patients and in the blood of 49 matching controls. In addition, we studied LINE-1 and Alu repeats using degenerate amplification approach as a surrogate marker for genome-wide methylation. The site-specific methylation measurements at selected CpG sites were done by the SIRPH method. Our results show that in the patient’s blood, tumor suppressor genes were slightly but significantly higher methylated at several CpG sites, while repeats were slightly less methylated compared to control blood. This was found to be significantly associated with higher risk for pancreatic ductal adenocarcinoma. Additionally, high methylation levels at TNFRSCF10C were associated with positive perineural spread of tumor cells, while higher methylation levels of TNFRSF10C and ACIN1 were significantly associated with shorter survival. This pilot study shows that methylation changes in blood could provide a promising method for early detection of pancreatic tumors. However, larger studies must be carried out to explore the clinical usefulness of a whole blood methylation based test for non-invasive early detection of pancreatic tumors.
References
[1]
Jemal A, Siegel R, Ward E, Murray T, Xu J, et al. (2006) Cancer statistics, 2006. CA Cancer J Clin 56: 106–130.
[2]
Riall TS, Cameron JL, Lillemoe KD, Winter JM, Campbell KA, et al. (2006) Resected periampullary adenocarcinoma: 5-year survivors and their 6- to 10-year follow-up. Surgery 140: 764–772.
[3]
Kanai Y (2008) Alterations of DNA methylation and clinicopathological diversity of human cancers. Pathol Int 58: 544–558. PIN2270 [pii];10.1111/j.1440–1827.2008.02270.x [doi].
[4]
Esteller M (2008) Epigenetics in cancer. N Engl J Med 358: 1148–1159.
[5]
Dammann R, Schagdarsurengin U, Seidel C, Strunnikova M, Rastetter M, et al. (2005) The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol 20: 645–663.
[6]
Fukushima N, Sato N, Ueki T, Rosty C, Walter KM, et al. (2002) Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol 160: 1573–1581.
[7]
Fukushima N, Sato N, Sahin F, Su GH, Hruban RH, et al. (2003) Aberrant methylation of suppressor of cytokine signalling-1 (SOCS-1) gene in pancreatic ductal neoplasms. Br J Cancer 89: 338–343.
[8]
Miyamoto K, Asada K, Fukutomi T, Okochi E, Yagi Y, et al. (2003) Methylation-associated silencing of heparan sulfate D-glucosaminyl 3-O-sulfotransferase-2 (3-OST-2) in human breast, colon, lung and pancreatic cancers. Oncogene 22: 274–280.
[9]
Esteller M, Corn PG, Baylin SB, Herman JG (2001) A gene hypermethylation profile of human cancer. Cancer Res 61: 3225–3229.
[10]
Fleisher AS, Esteller M, Tamura G, Rashid A, Stine OC, et al. (2001) Hypermethylation of the hMLH1 gene promoter is associated with microsatellite instability in early human gastric neoplasia. Oncogene 20: 329–335.
[11]
Machado JC, Oliveira C, Carvalho R, Soares P, Berx G, et al. (2001) E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. Oncogene 20: 1525–1528.
[12]
Viet CT, Schmidt BL (2008) Methylation array analysis of preoperative and postoperative saliva DNA in oral cancer patients. Cancer Epidemiol Biomarkers Prev 17: 3603–3611.
[13]
Belinsky SA, Palmisano WA, Gilliland FD, Crooks LA, Divine KK, et al. (2002) Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 62: 2370–2377.
[14]
Ahrendt SA, Chow JT, Xu LH, Yang SC, Eisenberger CF, et al. (1999) Molecular detection of tumor cells in bronchoalveolar lavage fluid from patients with early stage lung cancer. J Natl Cancer Inst 91: 332–339.
[15]
Goessl C, Muller M, Heicappell R, Krause H, Miller K (2001) DNA-based detection of prostate cancer in blood, urine, and ejaculates. Ann N Y Acad Sci 945: 51–58.
[16]
Muller HM, Oberwalder M, Fiegl H, Morandell M, Goebel G, et al. (2004) Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet 363: 1283–1285.
[17]
Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, et al. (2001) DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61: 1659–1665.
[18]
Hesson LB, Cooper WN, Latif F (2007) The role of RASSF1A methylation in cancer. Dis Markers 23: 73–87.
[19]
Mori T, O’Day SJ, Umetani N, Martinez SR, Kitago M, et al. (2005) Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol 23: 9351–9358.
[20]
Muller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, et al. (2003) DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res 63: 7641–7645.
[21]
Pedersen KS, Bamlet WR, Oberg AL, de AM, Matsumoto ME, et al. (2011) Leukocyte DNA methylation signature differentiates pancreatic cancer patients from healthy controls. PLoS One 6: e18223. 10.1371/journal.pone.0018223 [doi].
[22]
El-Maarri O, Herbiniaux U, Walter J, Oldenburg J (2002) A rapid, quantitative, non-radioactive bisulfite-SNuPE- IP RP HPLC assay for methylation analysis at specific CpG sites. Nucleic Acids Res 30: e25.
[23]
El-Maarri O (2004) SIRPH analysis: SNuPE with IP-RP-HPLC for quantitative measurements of DNA methylation at specific CpG sites. Methods Mol Biol 287: 195–205.
[24]
Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, et al. (2005) Analysis of repetitive element DNA methylation by MethyLight. Nucleic Acids Res 33: 6823–6836.
[25]
Choi JY, James SR, Link PA, McCann SE, Hong CC, et al. (2009) Association between global DNA hypomethylation in leukocytes and risk of breast cancer. Carcinogenesis 30: 1889–1897.
[26]
Hsiung DT, Marsit CJ, Houseman EA, Eddy K, Furniss CS, et al. (2007) Global DNA methylation level in whole blood as a biomarker in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 16: 108–114.
[27]
Moore LE, Pfeiffer RM, Poscablo C, Real FX, Kogevinas M, et al. (2008) Genomic DNA hypomethylation as a biomarker for bladder cancer susceptibility in the Spanish Bladder Cancer Study: a case-control study. Lancet Oncol 9: 359–366.
[28]
Lim U, Flood A, Choi SW, Albanes D, Cross AJ, et al. (2008) Genomic methylation of leukocyte DNA in relation to colorectal adenoma among asymptomatic women. Gastroenterology 134: 47–55.
[29]
Zhu ZZ, Sparrow D, Hou L, Tarantini L, Bollati V, et al. (2011) Repetitive element hypomethylation in blood leukocyte DNA and cancer incidence, prevalence, and mortality in elderly individuals: the Normative Aging Study. Cancer Causes Control 22: 437–447.
[30]
Wilhelm CS, Kelsey KT, Butler R, Plaza S, Gagne L, et al. (2010) Implications of LINE1 methylation for bladder cancer risk in women. Clin Cancer Res 16: 1682–1689. pp. 1078–0432.
[31]
Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Chan AT, et al. (2008) A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst 100: 1734–1738.
[32]
Hou L, Wang H, Sartori S, Gawron A, Lissowska J, et al. (2010) Blood leukocyte DNA hypomethylation and gastric cancer risk in a high-risk Polish population. Int J Cancer 127: 1866–1874.
[33]
Ohka F, Natsume A, Motomura K, Kishida Y, Kondo Y, et al. (2011) The Global DNA Methylation Surrogate LINE-1 Methylation Is Correlated with MGMT Promoter Methylation and Is a Better Prognostic Factor for Glioma. PLoS One 6: e23332.
[34]
Cho NY, Kim BH, Choi M, Yoo EJ, Moon KC, et al. (2007) Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. J Pathol 211: 269–277.
[35]
Shivapurkar N, Toyooka S, Toyooka KO, Reddy J, Miyajima K, et al. (2004) Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types. Int J Cancer 109: 786–792.
[36]
Cheng Y, Kim JW, Liu W, Dunn TA, Luo J, et al. (2009) Genetic and epigenetic inactivation of TNFRSF10C in human prostate cancer. Prostate 69: 327–335.
[37]
Suzuki M, Shigematsu H, Shivapurkar N, Reddy J, Miyajima K, et al. (2006) Methylation of apoptosis related genes in the pathogenesis and prognosis of prostate cancer. Cancer Lett 242: 222–230.
[38]
Shu Y, Iijima T, Sun W, Kano J, Ishiyama T, et al. (2006) The ACIN1 gene is hypermethylated in early stage lung adenocarcinoma. J Thorac Oncol 1: 160–167.
[39]
Frigola J, Sole X, Paz MF, Moreno V, Esteller M, et al. (2005) Differential DNA hypermethylation and hypomethylation signatures in colorectal cancer. Hum Mol Genet 14: 319–326.
[40]
Ehrlich M, Woods CB, Yu MC, Dubeau L, Yang F, et al. (2006) Quantitative analysis of associations between DNA hypermethylation, hypomethylation, and DNMT RNA levels in ovarian tumors. Oncogene 25: 2636–2645.
[41]
Lee HS, Kim BH, Cho NY, Yoo EJ, Choi M, et al. (2009) Prognostic implications of and relationship between CpG island hypermethylation and repetitive DNA hypomethylation in hepatocellular carcinoma. Clin Cancer Res 15: 812–820.
[42]
Ehrlich M (2009) DNA hypomethylation in cancer cells. Epigenomics 1: 239–259.
[43]
Shivapurkar N, Stastny V, Suzuki M, Wistuba II, Li L, et al. (2007) Application of a methylation gene panel by quantitative PCR for lung cancers. Cancer Lett 247: 56–71.
[44]
Liggett WH Jr, Sidransky D (1998) Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 16: 1197–1206.
[45]
Deng G, Song GA, Pong E, Sleisenger M, Kim YS (2004) Promoter methylation inhibits APC gene expression by causing changes in chromatin conformation and interfering with the binding of transcription factor CCAAT-binding factor. Cancer Res 64: 2692–2698.
[46]
Peng DF, Kanai Y, Sawada M, Ushijima S, Hiraoka N, et al. (2006) DNA methylation of multiple tumor-related genes in association with overexpression of DNA methyltransferase 1 (DNMT1) during multistage carcinogenesis of the pancreas. Carcinogenesis 27: 1160–1168.
[47]
Hoebeeck J, Michels E, Pattyn F, Combaret V, Vermeulen J, et al. (2009) Aberrant methylation of candidate tumor suppressor genes in neuroblastoma. Cancer Lett 273: 336–346.
[48]
Kito H, Suzuki H, Ichikawa T, Sekita N, Kamiya N, et al. (2001) Hypermethylation of the CD44 gene is associated with progression and metastasis of human prostate cancer. Prostate 49: 110–115.
[49]
Widschwendter M, Berger J, Muller HM, Zeimet AG, Marth C (2001) Epigenetic downregulation of the retinoic acid receptor-beta2 gene in breast cancer. J Mammary Gland Biol Neoplasia 6: 193–201.
[50]
Bernal C, Aguayo F, Villarroel C, Vargas M, Diaz I, et al. (2008) Reprimo as a potential biomarker for early detection in gastric cancer. Clin Cancer Res 14: 6264–6269. 14/19/6264 [pii];10.1158/1078-0432.CCR-07-4522 [doi].
[51]
Sobin LH, Wittekind C (2002) TNM classification of malignant tumors, 6th edn. UICC: Wiley-Liss 81–83:
